Core Viewpoint - The company has received approval from the China Securities Regulatory Commission to publicly issue corporate bonds totaling up to 2 billion yuan to professional investors [1] Group 1 - The company held its annual shareholder meeting in 2024, where it approved a proposal to register for corporate bonds and ultra-short-term financing bills [1] - The approval from the regulatory body allows the company to issue bonds with a total face value not exceeding 2 billion yuan, valid for 24 months from the date of approval [1] - The company has the option to issue the bonds in multiple tranches within the validity period of the registration [1]

Market Performance - The pharmaceutical commercial sector increased by 0.8% on January 12, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Top Gainers - RunDa Medical (603108) closed at 19.47, up 8.53%, with a trading volume of 1.0956 million shares and a transaction value of 2.123 billion [1] - Jia Shi Tang (002462) closed at 17.13, up 6.33%, with a trading volume of 441,200 shares and a transaction value of 733 million [1] - Yao Yi Gou (300937) closed at 38.42, up 4.54%, with a trading volume of 127,500 shares and a transaction value of 480 million [1] Top Losers - Nanjing Pharmaceutical (600713) closed at 5.43, down 1.63%, with a trading volume of 284,200 shares and a transaction value of 154 million [2] - Zhong Yao Holdings (000950) closed at 6.24, down 1.11%, with a trading volume of 740,900 shares and a transaction value of 461 million [2] - Ying Te Group (000411) closed at 12.81, down 1.08%, with a trading volume of 187,000 shares and a transaction value of 239 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 234 million from institutional investors and 184 million from speculative funds, while retail investors saw a net inflow of 417 million [2] - RunDa Medical had a net inflow of 123 million from institutional investors, but a net outflow of 171 million from speculative funds [3] - Jia Shi Tang experienced a net inflow of 80.845 million from institutional investors, with a net outflow of 28.7836 million from speculative funds [3]

转自：央视新闻 今天，国家医保局公布一起医生受贿案详情。全文如下： 2025年4月，黑龙江省铁力市人民法院依法公开审理了党某海犯非国家工作人员受贿罪一案。公诉机关 指控，2012年至2023年期间，被告人党某海在担任双丰林业局职工医院内科医生期间，利用开具处方的 职务便利，收受多家医药公司业务员和销售经理给予的药品回扣款，共计人民币789110元。具体事实如 下： 2. 2017年至2022年期间，被告人接受黑龙江省九昱医药有限责任公司销售经理孟某瑞的请托，为该公司 在提高销售药品数量上提供帮助，孟某瑞多次以微信转账、现金、银行转账等方式给予党某海药品回扣 款共计12.4万元。 3. 2013年至2022年期间，被告人接受黑龙江天德永珅医药有限公司、黑龙江省新龙医药有限公司业务员 谷某利的请托，为两家公司在提高销售药品数量上提供帮助，谷某利多次以微信转账和现金形式给予党 某海药品回扣款共计8.3万元。 4. 2017年至2023年期间，被告人党某海接受上药科园信海黑龙江医药有限公司业务员李某亮的请托，为 该公司在提高销售药品数量上提供帮助，李某亮分8次在医院附近给付党某海药品回扣款共计5.2万元。 5. 20 ...

涪陵榨菜：每10股派2.00元人民币现金（含税），股权登记日：2026-1-15，除息除权日：2026-1-16， 数据来源《2025年半年度权益分派实施公告》；申万一级行业：食品饮料，非红利低波 （H30269.CSI）成分股，非红利质量（931468.CSI）成分股。 招商银行：每股现金红利人民币1.013元（含税），股权登记日：2026-1-15，除息除权日：2026-1-16， 数据来源《2025年半年度A股分红派息实施公告》；申万一级行业：银行，是红利低波（H30269.CSI） 成分股，非红利质量（931468.CSI）成分股。 （文章来源：每日经济新闻） 红利低波（H30269.CSI）指数，选取50只流动性好、连续分红、红利支付率适中、每股股息正增长以 及股息率高且波动率低的证券作为指数样本，采用股息率加权，截至1月9日，该指数近1年股息率为 4.46%；红利低波ETF华夏（159547）是跟踪该指数综合费率最低的ETF，每季度评估可分红，联接基 金A类021482；联接基金C类021483。 红利质量（931468.CSI）指数，选取50只连续现金分红、股利支付率较高且兼具较高盈利能力特征的 ...

医药商业贿赂本质上是通过给予不正当利益影响处方权，干扰正常诊疗行为，妨碍公平竞争，加重医药 负担，使得医药产品销售从实际临床价值和产品的竞争力转为以高返点和高回扣驱动的不当竞争。司法 机关已经对行贿案件作出处罚，但案件暴露出的部分药品价格虚高空间依旧存在，虚高部分没有形成企 业正当盈利，也没有用于创新和质量，而是妨碍公平竞争。如不加以处置，虚高价格将持续侵害患者和 医保基金合法权益，也使合规经营企业受到错误示范。国家医保局于2020年建立价格招采信用评价制 度，对法院判决、有关部门查处的医药购销行贿、带金销售等问题突出的企业开展失信评级，并采取限 制挂网、配送等约束措施，使通过不当手段获取竞争优势的企业受相应约束，使合规经营企业感受公平 正义。 上海市药事所接到案源信息后，按规对涉案配送企业启动信用评价程序，要求配送企业指证失信行为的 实际控制主体。泓健医药公司提供了与河北常山生化药业公司关于涉案产品达肝素钠注射液的销售合 同、发票等信息，后续上海市药事所将对本案穿透至生产企业的河北常山生化药业公司启动信用评价。 2023年1月，当事人与上海泓健医药有限公司(以下简称"泓健医药公司")签订为期一年的《信息服务 ...

Group 1 - The company approved the use of up to 700 million yuan of temporarily idle raised funds for cash management, investing in low-risk, high-liquidity principal-protected financial products [1] - The cash management initiative is valid for 12 months from the date of board approval, with the option for rolling use and repayment to the dedicated fundraising account upon maturity [1] - On October 9, 2025, the subsidiary Fujian Tongchun Pharmaceutical Co., Ltd. purchased a large time deposit of 60 million yuan from China Merchants Bank, which matured on January 9, 2026, yielding a return of 165,000 yuan [2] Group 2 - The principal and earnings from the time deposit have been returned to the dedicated fundraising account, meeting the expected financial returns [2] - The company has been actively managing its raised funds over the past twelve months, indicating a strategic approach to financial management [2]

证券日报网讯1月9日，嘉事堂（002462）在互动平台回答投资者提问时表示，截至2025年12月19日，公 司股东共2.4万余户。 ...

证券日报网讯 1月9日，药易购在互动平台回答投资者提问时表示，投资者可参考定期报告中披露的股 东人数情况；如临时查询股东人数，可向公司提供股东持股证明以及个人身份证件等相关资料后，查询 对应信息。 （文章来源：证券日报） ...

Group 1 - The stock of Huaren Health increased by 9.97% with a turnover rate of 42.08%, and a total transaction amount of 1.365 billion yuan, showing a fluctuation of 9.86% [2] - Institutional investors net bought 15.1522 million yuan, while the Shenzhen Stock Connect saw a net purchase of 21.8482 million yuan, with a total net selling by brokerage seats amounting to 6.8363 million yuan [2] - The top five brokerage seats accounted for a total transaction of 293 million yuan, with a net purchase of 30.164 million yuan [2] Group 2 - In the past six months, the stock has appeared on the Dragon and Tiger list seven times, with an average price increase of 0.94% the day after being listed, but an average decline of 7.13% over the following five days [3] - The stock saw a net inflow of 31.3804 million yuan in main funds today, with a significant single net inflow of 42.4256 million yuan, while large single funds experienced a net outflow of 11.0452 million yuan [3] - The latest margin trading data shows a total margin balance of 226 million yuan, with a financing balance of 226 million yuan and a securities lending balance of 100.8 thousand yuan, indicating a recent increase in financing balance by 29.3529 million yuan, a rise of 14.95% [3]

Market Performance - The pharmaceutical commercial sector increased by 1.32% on January 9, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4120.43, up 0.92%, while the Shenzhen Component Index closed at 14120.15, up 1.15% [1] Top Gainers - RunDa Medical (603108) closed at 17.94, up 9.99% with a trading volume of 846,200 shares [1] - Huaren Health (301408) closed at 22.17, up 9.97% with a trading volume of 627,800 shares [1] - Shangyu Pingmin (301017) closed at 17.24, up 7.75% with a trading volume of 336,500 shares [1] Other Notable Stocks - Zhongyao Holdings (000950) closed at 6.31, up 5.87% with a trading volume of 1,147,000 shares [1] - Saily Medical (603716) closed at 27.83, up 4.39% with a trading volume of 783,100 shares [1] Market Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 122 million yuan from institutional investors and 174 million yuan from speculative funds, while retail investors saw a net inflow of 296 million yuan [2] - The trading volume and turnover for various stocks indicate a mixed sentiment among different investor categories [2] Individual Stock Fund Flow - RunDa Medical had a net inflow of 2.30 billion yuan from institutional investors, while it faced a net outflow of 1.36 billion yuan from speculative funds [3] - Zhongyao Holdings saw a net inflow of 61.04 million yuan from institutional investors, with a net outflow of 62.93 million yuan from retail investors [3] - The overall fund flow indicates varying levels of confidence among different investor types in the pharmaceutical sector [3]